Why Big Pharma Is Shifting Toward FSP Solutions

Samir Shah describes how large pharmaceutical companies are moving decisively toward FSP-derived models. He explains how AI investments, cost efficiency, and improved control over operations are driving a lasting structural shift — not a short-term trend — across the industry.